Table 4.
Comparison of TC changes in the TAF group compared to the TDF, inactive CHB, and non-HBV-infected control groups after propensity score matching
| Total cholesterol level | TAF (n=70) | TDF (n=140) | P-value | TAF (n=89) | Inactive CHB (n=89) | P-value | TAF (n=140) | Non-HBV-infected control (n=560) | P-value | |
|---|---|---|---|---|---|---|---|---|---|---|
| TC at baseline (mg/dL) | 172.8±31.5 | 168.8±30.8 | 0.193 | 164.5±35.0 | 163.6±25.0 | 0.840 | 168.4±33.1 | 168.6±29.0 | 0.999 | |
| TC at 24 weeks (mg/dL) | 174.4±29.8 | 157.4±27.4 | <0.001 | |||||||
| TC at 48 weeks (mg/dL) | 176.3±32.9 | 156.7±27.7 | <0.001 | 169.8±33.9 | 168.1±32.6 | 0.734 | 173.4±33.2 | 172.6±31.2 | 0.805 | |
| Delta-TC during 48 weeks | 1.8±22.4 | 4.5±24.2 | 0.438 | |||||||
| Delta-TC during 1 year | 2.9±25.2 | -11.9±26.5 | <0.001 | 4.7±25.7 | 4.0±26.5 | 0.768 | ||||
| TC at baseline (mg/dL) | ||||||||||
| 240≤ TC <300 | 1 (1.4) | 4 (2.9) | 0.873 | 1 (1.1) | 0 (0.0) | 1.000 | 2 (1.4) | 6 (1.1) | 1.000 | |
| ≥300 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||
| TC at 48 weeks (mg/dL) | ||||||||||
| 240≤ TC <300 | 1 (1.4) | 1 (0.7) | 1.000 | 1 (1.1) | 2 (2.2) | 1.000 | 3 (2.1) | 11 (2.0) | 1.000 | |
| ≥300 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||||
Values are presented as mean±standard deviation or number (%).
TC, total cholesterol; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; CHB, chronic hepatitis B; HBV, hepatitis B virus; delta-TC, total cholesterol changes during the observation period.